Citation Impact
Citing Papers
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
2023 Standout
Obesity and Kidney Disease: Hidden Consequences of the Epidemic
2017 Standout
An update on LDL apheresis for nephrotic syndrome
2018
Serum uric acid and cardiovascular disease: Recent developments, and where do they leave us?
2005
Das metabolisches Syndrom – ein umstrittenes diagnostisches Konzept
2007
Addressing the Global Cardiovascular Risk of Hypertension, Dyslipidemia, Diabetes Mellitus, and the Metabolic Syndrome in the Southeastern United States, Part II: Treatment Recommendations for Management of the Global Cardiovascular Risk of Hypertension, Dyslipidemia, Diabetes Mellitus, and the Metabolic Syndrome
2005
Can Statins Reduce Perioperative Morbidity and Mortality in Patients Undergoing Non-Cardiac Vascular Surgery?
2006
Emerging therapies for chronic kidney disease: what is their role?
2009
Do we need to consider inflammatory markers when we treat atherosclerotic disease?
2008
Targeting Ferroptosis to Iron Out Cancer
2019 Standout
Statins and proteinuria
2005
The impact of serum uric acid on cardiovascular outcomes in the LIFE study
2004
The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance
2011 Standout
Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease Prevention
2002
Physiology and immunology of the cholinergic antiinflammatory pathway
2007 Standout
An update on the lipid nephrotoxicity hypothesis
2009
Decreased heart rate variability is associated with higher levels of inflammation in middle-aged men
2008
Uric Acid and Cardiovascular Risk
2008 Standout
Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non‐alcoholic steatohepatitis
2007
Statins and C‐Reactive Protein Levels
2007
Intensity of Statin Therapy in Relation to Myocardial Ischemia, Troponin T Release, and Clinical Cardiac Outcome in Patients Undergoing Major Vascular Surgery
2007
A meta-analysis of heart rate variability and neuroimaging studies: Implications for heart rate variability as a marker of stress and health
2011 Standout
Gout
2009 Standout
Different Time Course for Prevention of Coronary and Stroke Events by Atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm (ASCOT-LLA)
2005
Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk
2010
Klotho Deficiency Causes Vascular Calcification in Chronic Kidney Disease
2010 Standout
2007 Guidelines for the Management of Arterial Hypertension
2007 Standout
A causal role for uric acid in fructose-induced metabolic syndrome
2005
PPARγ agonists exert antifibrotic effects in renal tubular cells exposed to high glucose
2005
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
2016 Standout
Regional Variation in Out-of-Hospital Cardiac Arrest Incidence and Outcome
2008 Standout
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
2010 Standout
Statins for Improving Renal Outcomes
2006
Association between Water Intake, Chronic Kidney Disease, and Cardiovascular Disease: A Cross-Sectional Analysis of NHANES Data
2013 Standout
Aortic Function: From the Research Laboratory to the Clinic
2012
Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis
2010
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
2013 Standout
A dose-response study of consuming high-fructose corn syrup–sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults
2015
Metabolic syndrome and eye diseases
2016
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
2003 Standout
An Overview of Heart Rate Variability Metrics and Norms
2017 Standout
Chronic kidney disease: global dimension and perspectives
2013 Standout
Oxidative stress in chronic kidney disease
2018 Standout
The triglyceride–high-density lipoprotein axis: An important target of therapy?
2004
Statins, inflammation and kidney disease
2011
Lifestyle and gout
2008
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
2012 Standout
Heart Rate, Life Expectancy and the Cardiovascular System: Therapeutic Considerations
2015 Standout
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study
2006
Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases
2008 Standout
Heart rate variability: a review
2006 Standout
Prevalence of diabetes mellitus and metabolic syndrome in Slovakia
2008
Global estimates of the prevalence of diabetes for 2010 and 2030
2009 Standout
Heart rate variability and cardiovascular mortality
2002
Are lipid-lowering drugs also antiarrhythmic drugs?
2003
Heart rate variability, overnight urinary norepinephrine, and plasma cholesterol in apparently healthy human adults
2011
Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences
2006
Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study
2006
High-Density Lipoprotein Subfractions - What the Clinicians Need to Know
2013 Standout
The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors
2009 Standout
Selenoproteins, Cholesterol-Lowering Drugs, and the Consequences Revisiting of the Mevalonate Pathway
2004
Management of Abdominal Aortic Aneurysms Clinical Practice Guidelines of the European Society for Vascular Surgery
2011 Standout
Dyslipidaemia of Obesity, Metabolic Syndrome and Type 2 Diabetes Mellitus: the Case for Residual Risk Reduction After Statin Treatment
2011
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Association of Drinking Pattern and Alcohol Beverage Type With the Prevalence of Metabolic Syndrome, Diabetes, Coronary Heart Disease, Stroke, and Peripheral Arterial Disease in a Mediterranean Cohort
2007
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 Standout
Genetics of the metabolic syndrome
2007
Prevention and Treatment of the Metabolic Syndrome
2004
The Tumor Lysis Syndrome
2011 Standout
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
2015 Standout
Pathophysiology of Type 2 Diabetes Mellitus
2020 Standout
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
2016 Standout
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
2011 Standout
Cataracts
2017 Standout
Metabolic Dysregulation and Adipose Tissue Fibrosis: Role of Collagen VI
2008 Standout
[767] METABOLIC SYNDROME IS ASSOCIATED WITH SEVERE FIBROSIS IN CHRONIC VIRAL HEPATITIS AND NON-ALCOHOLIC STEATOHEPATITIS
2007
The Metabolic Syndrome
2008 Standout
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
2016 Standout
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
2012 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack
2010 Standout
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
2018 Standout
Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health.
1998 Standout
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary
2018
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
2005 Standout
Works of A. Pehlivanidis being referenced
The prevalence of the metabolic syndrome in Greece: The MetS‐Greece Multicentre Study
2004
Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease.A subgroup analysis of the GREACE study
2005
Effect of atorvastatin on highdensity lipoprotein cholesteroland its relationship withcoronary events: a subgroupanalysis of the GREekAtorvastatin and Coronary-heart-disease Evaluation (GREACE) Study
2004
Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the greek atorvastatin and coronary-heart-disease evaluation (GREACE) study
2004
Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease
2004
The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study
2004
Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease
2001
Atorvastatin versus Four Statin-Fibrate Combinations in Patients with Familial Combined Hyperlipidaemia
2002
2002
Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients
2003
Early Benefit from Structured Care with Atorvastatin in Patients with Coronary Heart Disease and Diabetes Mellitus
2003